A biennial fecal immunochemical test-based CRC screening program can increase early-stage CRC detection and short-term survival.

A real-world analysis of nearly 7000 patients shows GLP-1s are associated with sharply lower death rates at 5 years in ...

Don’t wait for the first symptom. Start regular colorectal cancer screening at 45 years old to stay proactive about your ...

GLP-1 receptor agonists like Ozempic and Wegovy may increase survival among patients with colon cancer. | Drug Discovery And ...

Study researchers found no link between more liver fat and poor outcomes in patients with stage I-III rectal cancer.

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and ...

A new study from the University of California San Diego has found that popular diabetes and weight-loss medications might ...

One study found that vitamin D may have anticancer effects, which could help reduce colorectal cancer risk. Another piece of ...

NUS Medicine-led study shows extracellular vesicles carrying gene-targeting antisense oligonucleotides (ASOs) and immune ...

People with colon cancer who took GLP-1 drugs were less likely to die within 5 years than people not on GLP-1s, a new study ...

The FDA has approved a groundbreaking blood test for colon cancer screening, offering a less invasive and more accessible ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...